194 related articles for article (PubMed ID: 20885926)
21. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
[TBL] [Abstract][Full Text] [Related]
22. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.
Mirandola L; Figueroa JA; Phan TT; Grizzi F; Kim M; Rahman RL; Jenkins MR; Cobos E; Jumper C; Alalawi R; Chiriva-Internati M
Oncotarget; 2015 Feb; 6(5):2812-26. PubMed ID: 25739119
[TBL] [Abstract][Full Text] [Related]
23. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
24. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
25. Survivin--a universal tumor antigen.
Andersen MH; thor SP
Histol Histopathol; 2002 Apr; 17(2):669-75. PubMed ID: 11962766
[TBL] [Abstract][Full Text] [Related]
26. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
Chiriva-Internati M; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
[TBL] [Abstract][Full Text] [Related]
27. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy.
Zhang Y; Zhang Y; Zhang L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):281-291. PubMed ID: 30656409
[TBL] [Abstract][Full Text] [Related]
28. Sperm protein 17 is highly expressed in endometrial and cervical cancers.
Li FQ; Liu Q; Han YL; Wu B; Yin HL
BMC Cancer; 2010 Aug; 10():429. PubMed ID: 20712874
[TBL] [Abstract][Full Text] [Related]
29. PRAME peptide-specific CD8
Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
[TBL] [Abstract][Full Text] [Related]
30. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
31. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer.
Tammela J; Jungbluth AA; Qian F; Santiago D; Scanlan MJ; Keitz B; Driscoll D; Rodabaugh K; Lele S; Old LJ; Odunsi K
Cancer Immun; 2004 Oct; 4():10. PubMed ID: 15487888
[TBL] [Abstract][Full Text] [Related]
32. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
33. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M; Tono Y; Miyahara Y; Muraoka D; Harada N; Kageyama S; Sasaki T; Hori Y; Soga N; Uchida K; Shiraishi T; Sato E; Kanda H; Mizuno T; Webster GA; Ikeda H; Katayama N; Sugimura Y; Shiku H
Cancer Immunol Immunother; 2020 Apr; 69(4):663-675. PubMed ID: 31980914
[TBL] [Abstract][Full Text] [Related]
34. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
35. Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.
Liu R; Mitchell DA
Cancer Immunol Immunother; 2010 Feb; 59(2):183-93. PubMed ID: 19756596
[No Abstract] [Full Text] [Related]
36. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer.
Mirandola L; J Cannon M; Cobos E; Bernardini G; Jenkins MR; Kast WM; Chiriva-Internati M
Int Rev Immunol; 2011; 30(2-3):127-37. PubMed ID: 21557639
[TBL] [Abstract][Full Text] [Related]
37. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
Saito T; Wada H; Yamasaki M; Miyata H; Nishikawa H; Sato E; Kageyama S; Shiku H; Mori M; Doki Y
Vaccine; 2014 Oct; 32(45):5901-7. PubMed ID: 25218300
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
39. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.
Chiriva-Internati M; Yu Y; Mirandola L; Jenkins MR; Chapman C; Cannon M; Cobos E; Kast WM
PLoS One; 2010 May; 5(5):e10471. PubMed ID: 20485677
[TBL] [Abstract][Full Text] [Related]
40. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
Anderson KS; Ramachandran N; Wong J; Raphael JV; Hainsworth E; Demirkan G; Cramer D; Aronzon D; Hodi FS; Harris L; Logvinenko T; LaBaer J
J Proteome Res; 2008 Apr; 7(4):1490-9. PubMed ID: 18311903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
